{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=36",
    "query": {
      "intervention": "Placebo Saline Infusion",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 905,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:13:05.141Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00591318",
      "title": "A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psychosis",
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Foundation for Mental Hygiene, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-10-10",
      "completion_date": "2011-03-17",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591318"
    },
    {
      "nct_id": "NCT06825143",
      "title": "Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Vascular Injury",
        "Ischemic Preconditioning",
        "Endothelial Function (reactive Hyperemia)",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "Ischemic preconditioning",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravenous lactate infusion",
          "type": "DRUG"
        },
        {
          "name": "No ischemic preconditioning (control)",
          "type": "PROCEDURE"
        },
        {
          "name": "Normal Saline Infusion (Placebo)",
          "type": "DRUG"
        },
        {
          "name": "Ischemic preconditioning and intravenous lactate",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Gary Van Guilder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 68,
      "start_date": "2026-10-01",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 1,
      "location_summary": "Gunnison, Colorado",
      "locations": [
        {
          "city": "Gunnison",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06825143"
    },
    {
      "nct_id": "NCT01759862",
      "title": "Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Function of Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Aminophylline",
          "type": "DRUG"
        },
        {
          "name": "Theophylline drug levels",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 50,
      "start_date": "2012-11",
      "completion_date": "2017-07-25",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01759862"
    },
    {
      "nct_id": "NCT02974010",
      "title": "Sequential Therapy for the Treatment of Severe Bipolar Depression.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Depression",
        "Suicidal Ideas",
        "Suicidal Ideation",
        "Suicide, Attempted"
      ],
      "interventions": [
        {
          "name": "NRX-101 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ketamine Intravenous Infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution Intravenous Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2018-01-15",
      "completion_date": "2019-11-20",
      "has_results": true,
      "last_update_posted_date": "2021-05-25",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974010"
    },
    {
      "nct_id": "NCT05958342",
      "title": "CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Trauma",
        "Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Calcium Gluconate",
          "type": "DRUG"
        },
        {
          "name": "Vasopressin",
          "type": "DRUG"
        },
        {
          "name": "saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason Sperry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 1050,
      "start_date": "2024-06-30",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05958342"
    },
    {
      "nct_id": "NCT05778188",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypoxic-Ischemic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "RLS-0071",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReAlta Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "10 Hours",
        "sex": "ALL",
        "summary": "Up to 10 Hours"
      },
      "enrollment_count": 70,
      "start_date": "2023-07-27",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 15,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05778188"
    },
    {
      "nct_id": "NCT03008616",
      "title": "Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Preeclampsia"
      ],
      "interventions": [
        {
          "name": "AMAG-423 (digoxin immune fab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2017-04-12",
      "completion_date": "2020-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 16,
      "location_summary": "Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03008616"
    },
    {
      "nct_id": "NCT03834506",
      "title": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1030,
      "start_date": "2019-05-02",
      "completion_date": "2023-07-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 28,
      "location_summary": "Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03834506"
    },
    {
      "nct_id": "NCT03079921",
      "title": "Adrenergic System in Islet Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type1diabetes",
        "Hypoglycemia",
        "Hypoglycemia Unawareness",
        "Islet Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Phentolamine",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-01-20",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03079921"
    },
    {
      "nct_id": "NCT06079671",
      "title": "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "15 Years and older · Female only"
      },
      "enrollment_count": 800,
      "start_date": "2023-09-22",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-16T13:13:05.141Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06079671"
    }
  ]
}